Subodh Verma

Q: What Schools Are Affiliated With Subodh Verma

Subodh Verma is affiliated with the following schools: McGill University, Université de Montréal, University of Ottawa, McMaster University, RWTH Aachen University, University of Toronto, King Saud University

Subodh Verma's AcademicInfluence.com Rankings

Subodh Verma

Engineering

#2281

World Rank

#3167

Historical Rank

Biomedical Engineering

#50

World Rank

#50

Historical Rank

engineering Degrees

Download Badge

Engineering

Why Is Subodh Verma Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Subodh Verma's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. (2019) (2915)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. (2020) (1835)
A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis (2002) (1095)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. (2021) (1081)
Adipokines: molecular links between obesity and atheroslcerosis. (2005) (948)
New Markers of Inflammation and Endothelial Cell Activation: Part I (2003) (783)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. (2020) (736)
Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events (2019) (733)
Clinical and Pathophysiological Implications of a Bicuspid Aortic Valve (2002) (729)
Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction (2003) (677)
Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein (2002) (659)
Fundamentals of endothelial function for the clinical cardiologist. (2002) (647)
Endothelial function testing as a biomarker of vascular disease. (2003) (578)
C-Reactive Protein Attenuates Endothelial Progenitor Cell Survival, Differentiation, and Function: Further Evidence of a Mechanistic Link Between C-Reactive Protein and Cardiovascular Disease (2004) (573)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review (2018) (559)
C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle (2003) (557)
Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. (2006) (539)
Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. (2003) (452)
Endothelial cell control of thrombosis (2015) (441)
Restrictive or Liberal Red‐Cell Transfusion for Cardiac Surgery (2017) (432)
Fundamentals of reperfusion injury for the clinical cardiologist. (2002) (411)
Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation (2018) (377)
Valve-Related Hemodynamics Mediate Human Bicuspid Aortopathy: Insights From Wall Shear Stress Mapping. (2015) (336)
Microvascular Function Predicts Cardiovascular Events in Primary Prevention: Long-Term Results From the Firefighters and Their Endothelium (FATE) Study (2011) (329)
Endothelial progenitor cells: new hope for a broken heart. (2003) (295)
South Asians and cardiovascular risk: what clinicians should know. (2006) (284)
Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. (2008) (281)
Aortic dilatation in patients with bicuspid aortic valve. (2014) (278)
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. (2006) (275)
Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. (2016) (272)
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors (2020) (272)
MicroRNA-145 Targeted Therapy Reduces Atherosclerosis (2012) (266)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. (2020) (265)
Mechanical Stretch Regimen Enhances the Formation of Bioengineered Autologous Cardiac Muscle Grafts (2002) (250)
Empagliflozin Increases Cardiac Energy Production in Diabetes (2018) (244)
Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II (2003) (234)
Adropin Is a Novel Regulator of Endothelial Function (2010) (233)
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) (2019) (226)
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. (2022) (225)
Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. (2019) (224)
C-reactive protein comes of age (2005) (215)
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. (2016) (212)
Angiotensin receptor blockers and myocardial infarction (2004) (204)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease (2019) (200)
Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. (2010) (197)
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction (2019) (195)
Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db−/−) mice: role of decreased tetrahydrobiopterin bioavailability (2002) (191)
The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. (2020) (188)
TIMP-3 Deficiency Leads to Dilated Cardiomyopathy (2004) (187)
Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. (2013) (187)
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. (2016) (186)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? (2016) (185)
The Role of Autophagy in Vascular Biology (2015) (181)
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease. (2019) (172)
Inflammatory and Cholesterol Risk in the FOURIER Trial (2018) (172)
Adiponectin and cardiovascular disease: state of the art? (2007) (172)
2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. (2018) (171)
Rosiglitazone Facilitates Angiogenic Progenitor Cell Differentiation Toward Endothelial Lineage: A New Paradigm in Glitazone Pleiotropy (2004) (167)
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. (2017) (166)
Prevalence and Causes of Attrition Among Surgical Residents: A Systematic Review and Meta-analysis (2016) (163)
Six‐Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery (2018) (162)
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. (2011) (161)
Acute Spinal Cord Injury, Part II: Contemporary Pharmacotherapy (2001) (152)
The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve–related aortopathy: Full online‐only version (2018) (151)
Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease (2017) (150)
Obesity and atherosclerosis: mechanistic insights. (2015) (150)
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status (2020) (150)
Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. (2005) (146)
Clinician Guide to Angiogenesis (2003) (145)
The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors (2017) (144)
C-Reactive Protein Alters Antioxidant Defenses and Promotes Apoptosis in Endothelial Progenitor Cells (2006) (143)
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction (2020) (142)
Cardiac remodeling and failure From molecules to man (Part II). (2005) (134)
The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. (2017) (134)
Concise Review: Cell Therapy for Critical Limb Ischemia: An Integrated Review of Preclinical and Clinical Studies (2018) (131)
Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. (2002) (131)
Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. (2014) (129)
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure (2017) (129)
Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. (2019) (128)
Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. (2006) (128)
Insulin Action in the Vasculature: Physiology and Pathophysiology (2001) (125)
Targeting cardiovascular inflammation: next steps in clinical translation. (2020) (124)
C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation. (2003) (123)
Empagliflozin's Fuel Hypothesis: Not so Soon. (2016) (122)
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. (2017) (121)
Pregnancy-Related Spontaneous Coronary Artery Dissection (2014) (121)
C-Reactive Protein: Structure Affects Function (2004) (119)
The T-786→C Mutation in Endothelial Nitric Oxide Synthase Is Associated With Hypertension (2002) (117)
BRCA1 is an essential regulator of heart function and survival following myocardial infarction (2011) (116)
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy (2020) (114)
Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials (2015) (111)
Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. (2003) (110)
Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. (2006) (109)
SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects (2019) (108)
C-Reactive Protein Upregulates Complement-Inhibitory Factors in Endothelial Cells (2004) (105)
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. (2013) (104)
miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. (2012) (104)
Cardiac remodeling and failure: from molecules to man (Part III). (2005) (103)
Evolving role of microparticles in the pathophysiology of endothelial dysfunction. (2013) (102)
Ross Procedure in Adults for Cardiologists and Cardiac Surgeons: JACC State-of-the-Art Review. (2018) (99)
Altered Expression of Disintegrin Metalloproteinases and Their Inhibitor in Human Dilated Cardiomyopathy (2006) (99)
Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice (2003) (99)
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure (2020) (98)
Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. (2008) (96)
C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. (2003) (96)
Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. (2005) (94)
New Developments in the Treatment of Hypoplastic Left Heart Syndrome (2007) (94)
Role of Endothelium in Doxorubicin-Induced Cardiomyopathy (2018) (93)
Intact endothelial autophagy is required to maintain vascular lipid homeostasis (2015) (92)
Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. (2009) (91)
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. (2021) (90)
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. (2020) (89)
Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. (2017) (89)
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF (2020) (89)
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. (2009) (88)
Knowledge, attitudes, and practice patterns in surgical management of bicuspid aortopathy: a survey of 100 cardiac surgeons. (2013) (87)
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial (2021) (87)
Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. (2011) (84)
Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes. (2017) (84)
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial (2021) (83)
Stem Cell Factor Deficiency Is Vasculoprotective: Unraveling a New Therapeutic Potential of Imatinib Mesylate (2006) (83)
Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease - executive summary. (2005) (83)
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial (2018) (81)
Should radial arteries be used routinely for coronary artery bypass grafting? (2004) (78)
Cyclooxygenase-2 Blockade Does Not Impair Endothelial Vasodilator Function in Healthy Volunteers: Randomized Evaluation of Rofecoxib Versus Naproxen on Endothelium-Dependent Vasodilatation (2001) (78)
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. (2020) (77)
Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle cell activation: the PATENT saphenous vein graft study. (2014) (77)
Mitral-valve repair for mitral-valve prolapse. (2009) (77)
Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals. (2004) (77)
Cardiac remodeling and failure: from molecules to man (Part I). (2005) (75)
The Essential Autophagy Gene ATG7 Modulates Organ Fibrosis via Regulation of Endothelial-to-Mesenchymal Transition* (2014) (75)
Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: reversal with endothelin antagonism. (2002) (73)
Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors. (2009) (73)
Impaired endothelial function in C-reactive protein overexpressing mice. (2008) (73)
Antiatherogenic potential of red wine: clinician update. (2005) (72)
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) (2020) (72)
A systematic review and meta-analysis of the long-term outcomes of endovascular versus open repair of abdominal aortic aneurysm. (2019) (72)
Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention (2015) (72)
Bicuspid aortic valve disease: recent insights in pathophysiology and treatment (2005) (71)
Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). (2011) (70)
C-Reactive Protein Upregulates Receptor for Advanced Glycation End Products Expression in Human Endothelial Cells (2006) (70)
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial (2020) (70)
Red Wine and Your Heart (2005) (70)
Glitazones and heart failure: critical appraisal for the clinician. (2003) (69)
Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. (2019) (69)
Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials (2015) (69)
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke: Post Hoc Analysis From the LEADER Trial (2018) (66)
Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta‐Analysis (2018) (64)
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. (2018) (61)
Stem Cell Factor Attenuates Vascular Smooth Muscle Apoptosis and Increases Intimal Hyperplasia After Vascular Injury (2007) (61)
The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve–related aortopathy: Executive summary (2018) (61)
Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease. (2016) (61)
Rate, Timing, Correlates, and Outcomes of Hemodynamic Valve Deterioration After Bioprosthetic Surgical Aortic Valve Replacement (2018) (61)
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? (2017) (59)
SUPERIOR SVG: no touch saphenous harvesting to improve patency following coronary bypass grafting (a multi-Centre randomized control trial, NCT01047449) (2019) (58)
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits. (2019) (57)
Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. (2003) (57)
Abstract 14465: Loss of BRCA2 in the Heart Induces Age-Related Cardiomyopathy (2012) (57)
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial (2021) (56)
Impact of total arterial revascularization on long term survival: A systematic review and meta-analysis of 130,305 patients. (2017) (55)
Pump, pipes, and filter: do SGLT2 inhibitors cover it all? (2019) (55)
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. (2017) (55)
Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. (2002) (54)
Adiponectin and myocardial infarction: A paradox or a paradigm? (2006) (53)
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (53)
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. (2019) (53)
Surgical Management of Infective Endocarditis Complicated by Embolic Stroke: Practical Recommendations for Clinicians (2016) (52)
The Serendipitous Story of SGLT2 Inhibitors in Heart Failure. (2019) (52)
Cell transplantation preserves matrix homeostasis: a novel paracrine mechanism. (2005) (52)
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial (2019) (51)
Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. (2019) (51)
BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis. (2013) (51)
Ethnic diversity: South Asian ethnicity is associated with increased coronary artery bypass grafting mortality. (2007) (49)
Systematic review and meta‐analysis of chordal replacement versus leaflet resection for posterior mitral leaflet prolapse (2018) (49)
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease (2020) (49)
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. (2022) (47)
Cardiology patient page. Statin intolerance. (2015) (47)
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights. (2017) (46)
Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus (2015) (46)
The differential association between various anthropometric indices of obesity and subclinical atherosclerosis. (2009) (46)
Mechanical circulatory assistance: state of art. (2002) (45)
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. (2020) (45)
Autophagy gene fingerprint in human ischemia and reperfusion. (2014) (45)
Ross Procedure vs Mechanical Aortic Valve Replacement in Adults: A Systematic Review and Meta-analysis (2018) (44)
Variability in vascular smooth muscle cell stretch-induced responses in 2D culture (2015) (43)
Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: reversal by means of endothelin antagonism. (2002) (43)
Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management. (2012) (42)
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF (2020) (42)
A systematic review and meta‐analysis of in situ versus composite bilateral internal thoracic artery grafting (2017) (41)
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. (2019) (41)
Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells. (2004) (41)
Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances. (2018) (40)
BRCA2 Protein Deficiency Exaggerates Doxorubicin-induced Cardiomyocyte Apoptosis and Cardiac Failure* (2011) (40)
Integrin-linked kinase mediates force transduction in cardiomyocytes by modulating SERCA2a/PLN function (2014) (40)
Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. (2021) (39)
Cardiovascular Protection in People With Diabetes. (2018) (39)
Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction. (2009) (38)
Cyclosporine increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. (2008) (37)
Symptomatic graft failure and impact on clinical outcome after coronary artery bypass grafting surgery: Results from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry. (2015) (37)
Off-pump coronary artery bypass surgery: fundamentals for the clinical cardiologist. (2004) (37)
Reduction in Revascularization With Icosapent Ethyl (2020) (36)
Idiopathic pulmonary fibrosis--new insights. (2007) (36)
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction (2020) (36)
The fate of endothelial function testing: rationale and design of the Firefighters And Their Endothelium (FATE) study. (2003) (36)
Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome (2008) (36)
Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. (2009) (36)
DNA damage repair and cardiovascular diseases. (2010) (35)
Population-based secular trends in lower-extremity amputation for diabetes and peripheral artery disease (2019) (35)
Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) (35)
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. (2020) (34)
The ten most commonly asked questions about endothelial function in cardiology. (2001) (34)
Tetrahydrobiopterin attenuates homocysteine induced endothelial dysfunction (2003) (34)
The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. (2019) (34)
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial (2020) (33)
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study (2020) (33)
Cardiology patient pages. Red wine and your heart. (2005) (32)
Nitric oxide-eluting polyurethanes--vascular grafts of the future? (2005) (32)
Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure (2020) (32)
The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial. (2020) (32)
Endocarditis in the setting of IDU: multidisciplinary management (2017) (31)
Comparison of Outcomes in Elective Endovascular Aortic Repair vs Open Surgical Repair of Abdominal Aortic Aneurysms (2019) (31)
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. (2021) (30)
Direct innominate artery cannulation for selective antegrade cerebral perfusion during deep hypothermic circulatory arrest in aortic surgery. (2014) (30)
Surgical Management of Tricuspid Valve Infective Endocarditis: A Systematic Review and Meta-Analysis. (2018) (30)
Empagliflozin restores the integrity of the endothelial glycocalyx in vitro (2019) (29)
L-arginine protects human heart cells from low-volume anoxia and reoxygenation. (2002) (29)
Diabetes Canada Position Statement for People With Types 1 and 2 Diabetes Who Fast During Ramadan. (2019) (29)
Role of endothelial primary cilia as fluid mechanosensors on vascular health. (2018) (29)
Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. (2005) (28)
What Surgeons Should Know About Non–Vitamin K Oral Anticoagulants: A Review (2018) (28)
C-reactive protein incites atherosclerosis. (2004) (28)
Empagliflozin improves left ventricular diastolic function of db/db mice. (2020) (28)
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. (2019) (27)
CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More. (2017) (27)
A Systematic Review and Meta-Analysis of del Nido Versus Conventional Cardioplegia in Adult Cardiac Surgery (2019) (26)
The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis. (2006) (26)
Clinical Decision Making for Endovascular Repair of Abdominal Aortic Aneurysm (2004) (26)
Loss of vascular smooth muscle cell autophagy exacerbates angiotensin II‐associated aortic remodeling (2017) (26)
Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. (2019) (26)
Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study. (2008) (25)
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial (2021) (25)
Sex differences in the outcomes of peripheral arterial disease: a population-based cohort study. (2016) (25)
Adiponectin limits monocytic microparticle-induced endothelial activation by modulation of the AMPK, Akt and NFκB signaling pathways. (2016) (25)
The relationship between anthropometric indexes of adiposity and vascular function in the FATE cohort (2012) (25)
Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. (2019) (25)
Safety of a Restrictive versus Liberal Approach to Red Blood Cell Transfusion on the Outcome of AKI in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial. (2019) (25)
Early vs Late Surgery for Patients With Endocarditis and Neurological Injury: A Systematic Review and Meta-analysis. (2018) (25)
Dual antiplatelet therapy use by Canadian cardiac surgeons. (2015) (25)
Endothelial long non-coding RNAs regulated by oxidized LDL (2017) (25)
Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach (2018) (25)
Can statin therapy alter the natural history of bicuspid aortic valves? (2005) (25)
Serum interleukin-6 levels, not genotype, correlate with coronary plaque complexity. (2008) (25)
Altered branched chain amino acid metabolism: toward a unifying cardiometabolic hypothesis (2018) (24)
Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization (2018) (24)
Statin Effects on LDL and HDL Cholesterol in South Asian and White Populations (2009) (24)
The putative role of autophagy in the pathogenesis of abdominal aortic aneurysms. (2017) (24)
A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs. (2016) (24)
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. (2016) (23)
DIRECT EFFECTS OF EMPAGLIFLOZIN ON EXTRACELLULAR MATRIX REMODELING IN HUMAN CARDIAC FIBROBLASTS: NOVEL TRANSLATIONAL CLUES TO EMPA-REG OUTCOME (2017) (23)
Prevalence of Elective and Ruptured Abdominal Aortic Aneurysm Repairs by Age and Sex From 2003 to 2016 in Ontario, Canada (2018) (23)
Endothelial function: ready for prime time? (2004) (23)
A practical clinical approach to utilize cardiopulmonary exercise testing in the evaluation and management of coronary artery disease: a primer for cardiologists (2017) (23)
Impact of diabetes on carotid artery revascularization. (2016) (22)
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials (2020) (22)
Surgical Management of Ischemic Mitral Regurgitation (2009) (22)
Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes? (2018) (22)
Frailty and pre-frailty in cardiac surgery: a systematic review and meta-analysis of 66,448 patients (2021) (22)
Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. (2018) (22)
Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications. (2013) (22)
Investigation of novel LPS-induced differentially expressed long non-coding RNAs in endothelial cells (2016) (22)
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial (2021) (21)
Association of Apolipoproteins B and A-1 With Markers of Vascular Health or Cardiovascular Events. (2017) (21)
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction (2021) (21)
Year in review: bicuspid aortopathy (2016) (21)
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial (2019) (21)
Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME (2020) (21)
Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. (2005) (21)
Perceptions of Canadian Vascular Surgeons toward Pharmacological Risk Reduction in Patients with Peripheral Arterial Disease (2006) (21)
A Big Win for Diabetic Kidney Disease: CREDENCE. (2019) (21)
Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications. (2018) (21)
Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injury. (2005) (20)
Innominate and Axillary Cannulation in Aortic Arch Surgery Provide Similar Neuroprotection. (2016) (20)
Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia (2018) (20)
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials (2021) (20)
Endothelial progenitor cell-coated stents under scrutiny. (2006) (20)
Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG. (2021) (20)
Restoration and regeneration of failing myocardium with cell transplantation and tissue engineering. (2003) (19)
Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. (2011) (19)
Long-term Outcomes of Carotid Endarterectomy Versus Stenting in a Multicenter Population-based Canadian Study (2017) (19)
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials (2019) (19)
See one, simulate many, do one, teach one: cardiac surgical simulation. (2019) (19)
Endothelial‐specific deletion of autophagy‐related 7 (ATG7) attenuates arterial thrombosis in mice (2017) (19)
Management of postoperative atrial fibrillation after cardiac surgery (2016) (19)
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF (2022) (19)
Targeting Inflammation in the Prevention and Treatment of Type 2 Diabetes: Insights From CANTOS. (2018) (18)
Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?∗ (2020) (18)
Update on rheumatic heart disease (2016) (18)
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial (2020) (17)
Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results. (2009) (17)
The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. (2005) (17)
Regression of aortic aneurysms through pharmacologic therapy? (2006) (17)
Anticoagulation for prosthetic heart valves: unresolved questions requiring answers (2016) (17)
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure (2021) (17)
Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery (2021) (17)
The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. (2020) (17)
Association between operator specialty and outcomes after carotid artery revascularization. (2017) (17)
Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials (2021) (17)
Insulin resistance as a therapeutic target for improved endothelial function: metformin. (2004) (17)
The effect of iron status on vascular health (2006) (17)
BRCA1 shields vascular smooth muscle cells from oxidative stress. (2014) (17)
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF (2022) (16)
Renin-angiotensin system blockade does not attenuate abdominal aortic aneurysm growth, rupture rate, or perioperative mortality after elective repair. (2017) (16)
Investigation of TGFβ1-Induced Long Noncoding RNAs in Endothelial Cells (2016) (16)
Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1. (2013) (16)
Association between sepsis survivorship and long-term cardiovascular outcomes in adults: a systematic review and meta-analysis (2021) (16)
The molecular fingerprint of bicuspid aortopathy. (2013) (16)
Two Randomized Clinical Trials on the Treatment of Secondary Mitral Regurgitation-Contradictory or Complementary? (2019) (16)
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF (2020) (15)
Optimizing Foundational Therapies in Patients With HFrEF (2022) (15)
Subclinical bioprosthetic aortic valve thrombosis: clinical and translational implications (2016) (15)
The coronary heart team (2017) (15)
Altered coagulation profile in peripheral artery disease patients (2020) (15)
Bicuspid aortic valve aortopathy: mechanistic and clinical insights from recent studies (2016) (15)
Recent cannabis use and myocardial infarction in young adults: a cross-sectional study (2021) (15)
Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 randomised trial (2017) (15)
Bicuspid aortopathy and the development of individualized resection strategies. (2014) (14)
Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective (2020) (14)
Knowledge, attitudes, and practice preferences of Canadian cardiac surgeons toward the management of acute type A aortic dissection. (2015) (14)
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction (2020) (14)
Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes (2018) (14)
Caveolin: A key target for modulating nitric oxide availability in health and disease (2003) (14)
C-reactive protein and the metabolic syndrome: useful addition to the cardiovascular risk profile? (2006) (14)
Risk of intracranial hemorrhage after carotid artery stenting versus endarterectomy: a population-based study. (2018) (14)
Predictors of heart failure development in type 2 diabetes: a practical approach (2019) (14)
Diabetic Heart Dysfunction: Is Cell Transplantation a Potential Therapy? (2003) (14)
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19 (2021) (14)
Platelet Transfusion in Cardiac Surgery: A Systematic Review and Meta-Analysis. (2020) (13)
Clinical outcomes of mitral valve intervention in patients with mitral annular calcification: A systematic review and meta‐analysis (2020) (13)
Therapeutic targeting of inflammation in atherosclerosis: we are getting closer. (2012) (13)
Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis (2020) (13)
Drawbacks to stem cell therapy in cardiovascular diseases. (2008) (13)
Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results). (2007) (13)
Endothelin blockade potentiates endothelial protective effects of ACE inhibitors in saphenous veins. (2002) (13)
Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial) (2017) (13)
Bicuspid aortic valve-associated aortopathy: update on biomarkers (2017) (13)
Validation of abdominal aortic aneurysm repair codes in Ontario administrative data. (2018) (12)
Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. (2020) (12)
Latest evidence on transcatheter aortic valve implantation vs. surgical aortic valve replacement for the treatment of aortic stenosis in high and intermediate-risk patients (2017) (12)
Fingerprint of long non-coding RNA regulated by cyclic mechanical stretch in human aortic smooth muscle cells: implications for hypertension (2017) (12)
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials (2020) (12)
Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. (2017) (12)
Function determines structure in the vasculature: lessons from insulin resistance. (2005) (12)
The endocannabinoid system and cardiometabolic risk. (2008) (12)
Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon? (2017) (12)
Inhibition of the renin-angiotensin system in cardiovascular protection: Is it important to watch your C'ARB' intake? (2005) (12)
Carotid Artery Revascularization: What’s the Best Strategy? (2015) (12)
Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. (2019) (12)
Perceptions of Canadian Vascular Surgeons Toward Pharmacologic Risk Reduction in Patients with Peripheral Artery Disease: 2018 Update. (2019) (11)
Cardiovascular inflammation is reduced with methotrexate in diabetes (2017) (11)
Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE. (2005) (11)
The Serendipitous Story of SGLT 2 Inhibitors in Heart Failure : New Insights from DECLARE-TIMI 58 Running (2019) (11)
The incretin system and cardiometabolic disease. (2010) (11)
Suboptimal use of risk reduction therapy in peripheral arterial disease patients at a major teaching hospital (2011) (11)
Two Tales: One Story. EMPEROR-Reduced and DAPA-HF. (2020) (11)
Utilizing wall shear stress as a clinical biomarker for bicuspid valve-associated aortopathy (2019) (11)
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI (2022) (11)
Coronary Artery Bypass Graft for Anomalous Right Coronary Artery (2011) (11)
Nocturnal haemodialysis is associated with improved vascular smooth muscle cell biology. (2009) (11)
Transcatheter Aortic Valve Replacement in Low-Risk Patients. (2019) (11)
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial (2021) (11)
More CREDENCE for SGLT2 Inhibition. (2019) (11)
Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis (2022) (10)
The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization. (2021) (10)
Oral anticoagulation for stroke prevention amongst atrial fibrillation patients with valvular heart disease: an update (2016) (10)
Effects of long-term chloroquine administration on the natural history of aortic aneurysms in mice. (2015) (10)
C-reactive protein, metabolic syndrome, and end organ damage. (2007) (10)
Sutureless aortic valves: who is the right patient? (2017) (10)
A systematic review and meta-analysis of plain versus drug-eluting balloon angioplasty in the treatment of juxta-anastomotic hemodialysis arteriovenous fistula stenosis. (2020) (10)
Aliskiren improves nitric oxide bioavailability and limits atherosclerosis. (2008) (10)
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery (2021) (10)
Intracranial Hemorrhage During Dual Antiplatelet Therapy: JACC Review Topic of the Week. (2021) (10)
Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease (2010) (10)
Dulaglutide and renal protection in type 2 diabetes. (2018) (10)
The Management of Antiplatelet and Antithrombotic Regimens in Patients With Mechanical Valves Undergoing Percutaneous Coronary Intervention: A Forgotten Cohort? (2017) (10)
SGLT2 inhibitors: practical considerations and recommendations for cardiologists. (2018) (10)
Does Ischemic Preconditioning Afford Clinically Relevant Cardioprotection? (2003) (10)
Perioperative cardiovascular system failure in South Asians undergoing cardiopulmonary bypass is associated with prolonged inflammation and increased Toll-like receptor signaling in inflammatory monocytes. (2014) (9)
Prevention of Heart Failure With SGLT-2 Inhibition: Insights From CVD-REAL. (2018) (9)
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. (2022) (9)
Randomized, Controlled Trial Comparing Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis (2020) (9)
Endothelin Antagonism and Insulin's Vascular Effects. (2002) (9)
Homograft versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis (2018) (9)
The economic burden of inpatient diabetic foot ulcers in Toronto, Canada (2020) (9)
IMPACT OF TOTAL ARTERIAL REVASCULARIZATION ON LONG-TERM SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 130,305 PATIENTS (2017) (9)
Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease. (2022) (9)
Population-based long-term outcomes of open versus endovascular aortic repair of ruptured abdominal aortic aneurysms. (2020) (9)
Peripheral artery disease among Indigenous Canadians: What do we know? (2018) (9)
Hemoglobin Optimization for Coronary Bypass: A 10-Year Canadian Multicenter Experience. (2019) (9)
Primary prevention of cardiovascular disease: global cardiovascular risk assessment and management in clinical practice. (2015) (9)
Risk of Acute Kidney Injury in Patients Randomized to a Restrictive Versus Liberal Approach to Red Blood Cell Transfusion in Cardiac Surgery: A Substudy Protocol of the Transfusion Requirements in Cardiac Surgery III Noninferiority Trial (2018) (9)
A novel role of endothelial autophagy as a regulator of myocardial fatty acid oxidation (2019) (9)
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction (2022) (8)
Abstract 1134: Plasma Renin Activity is Associated With Increased Cardiovascular Events and Mortality in the HOPE Study (2009) (8)
Practical Considerations and Rationale for Glucagon-like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. (2020) (8)
271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF (2020) (8)
Coxibs and the endothelium. (2003) (8)
Genetic abnormalities of the endothelium (2003) (8)
A randomized trial comparing axillary versus innominate artery cannulation for aortic arch surgery. (2020) (8)
The perils of polyvascular disease in type 2 diabetes. (2018) (8)
Pharmacodynamic and clinical implications of switching between P2Y12 receptor antagonists: considerations for practice. (2014) (8)
Transcatheter Tricuspid Repair With MitraClip for Severe Primary Tricuspid Regurgitation. (2016) (8)
Knock‐out of MicroRNA 145 impairs cardiac fibroblast function and wound healing post‐myocardial infarction (2020) (8)
Is There a Role for Colchicine in Acute Coronary Syndromes? (2015) (8)
Magna Ease versus Trifecta Early Hemodynamics (2018) (8)
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials (2020) (8)
Blood Pressure, Hypertension, and the Risk of Aortic Dissection Incidence and Mortality: Results From the J-SCH Study, the UK Biobank Study, and a Meta-Analysis of Cohort Studies (2021) (8)
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial (2020) (8)
Long-Term Outcomes of Post-Operative Atrial Fibrillation: Guilty as Charged. (2018) (8)
What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis? (2017) (8)
The Cost of Frailty in Cardiac Surgery. (2017) (8)
Cardiac Surgery in HIV Patients: State of the Art. (2019) (8)
Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery (2020) (8)
Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes. (2004) (8)
Coenzyme Q(10) and congestive heart failure: what is the verdict? (2002) (7)
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial (2021) (7)
Position Statement Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group Cardiometabolic Risk Working Group: Executive Committee: (2011) (7)
Anticoagulation Following TAVR: No Clear Answer Yet. (2019) (7)
Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS‐HFDM) in patients in the ACCORD trial (2021) (7)
C-reactive protein and statins: IL-8 as a molecular link? (2005) (7)
Knowledge gap of peripheral artery disease starts in medical school. (2019) (7)
Apelin increases atrial conduction velocity, refractoriness, and prevents inducibility of atrial fibrillation (2020) (7)
Cardiology Patient Page: coronary artery revascularization in patients with diabetes mellitus. (2014) (7)
Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. (2021) (7)
Functional mitral stenosis following mitral valve repair (2016) (7)
Does cannabis hold the key to treating cardiometabolic disease? (2006) (7)
Myocardial infarction with nonobstructive coronary artery disease (MINOCA): a review of pathophysiology and management (2021) (7)
Mechanisms by which GLP-1 receptor agonists and SGLT-2 inhibitors reduce cardiovascular risk (2019) (7)
Mitral valve prosthesis choice in patients <70 years: A systematic review and meta‐analysis of 20 219 patients (2020) (7)
Preservation of heart function in diabetic rats by the combined effects of muscle cell implantation and insulin therapy (2008) (7)
Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME (2021) (6)
Metformin: An Old Dog with a New Trick? (2018) (6)
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling (2022) (6)
DAPA-CKD (2021) (6)
Evaluation of a novel sutureless anastomotic connector: from endothelial function to mid-term clinical and angiographic follow-up. (2003) (6)
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) (6)
Prognostic Implications of N-terminal Pro-B Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. (2022) (6)
Effects of folinic acid on forearm blood flow in patients with end-stage renal disease. (2006) (6)
Prediction of Heart Failure Outcomes in Patients with Type 2 Diabetes Mellitus: Validation of the TRS-HFDM Score in the ACCORD Trial. (2020) (6)
The Current Status of Lithoplasty in Vascular Calcifications: A Systematic Review (2019) (6)
Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease? (2021) (6)
EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL (2019) (6)
Disruption of endothelial cell intraflagellar transport protein 88 exacerbates doxorubicin-induced cardiotoxicity. (2020) (6)
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits (2019) (6)
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. (2021) (6)
Innovations in tricuspid valve intervention (2017) (6)
Working heart function in diabetes is not improved by spironolactone treatment. (2003) (6)
Rivaroxaban in peripheral artery disease: The new kid on the block? (2018) (5)
Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit? (2021) (5)
Subclinical Valve Thrombosis in Sutureless Bioprosthetic Valves (2017) (5)
Cardiometabolic risk factor control in black and white people in the United States initiating sodium‐glucose co‐transporter‐2 inhibitors: A real‐world study (2020) (5)
Loss of endothelial cell-specific autophagy-related protein 7 exacerbates doxorubicin-induced cardiotoxicity (2019) (5)
Should Bioprosthetic Aortic Valves Be Routinely Anticoagulated?: Insights From PARTNER and Beyond. (2019) (5)
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. (2022) (5)
Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications (2018) (5)
Thirty-day hospital readmission and emergency department visits after vascular surgery: a Canadian prospective cohort study. (2018) (5)
Generalizability of Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial in patients with a history of coronary artery bypass graft surgery. (2020) (5)
COMPASS for Vascular Surgeons: Practical Considerations (2019) (5)
Abstract 14806: The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Most Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials (2018) (5)
Aortic valve malformations and pulmonary autograft root dilatation. (2002) (5)
Ticagrelor use and practice patterns among Canadian cardiac surgeons (2021) (5)
Bilateral internal thoracic arteries: what is the State of the ART? (2017) (5)
Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge. (2019) (5)
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. (2022) (5)
Vascular dysfunction: a Janus face of visfatin in diabetes? (2007) (5)
Evolving Surgical Approaches to Bicuspid Aortic Valve Associated Aortopathy (2019) (5)
Pharmacological modulation of insulin resistance and hyperinsulinemia in polycystic ovary syndrome: The emerging role (1998) (5)
Vascular biology of adiponectin (2008) (5)
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease (2022) (5)
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection (2022) (4)
Learning curve predictors for minimally invasive mitral valve surgery; how far should the rabbit hole go? (2020) (4)
Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trial. (2021) (4)
Cardiometabolic Risk Factor Control in African American and White Caucasians initiating SGLT-2 Inhibitor: Real-world Study. (2020) (4)
SURGICAL MANAGEMENT OF TRICUSPID VALVE INFECTIVE ENDOCARDITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS (2017) (4)
Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET) (2022) (4)
Fish oil supplementation and arrhythmias. (2005) (4)
Aortic Valve Replacement in an Era of Rapid Innovation: Better the Devil You Know. (2018) (4)
Early failure of aortic bioprostheses: what are the mechanisms? (2019) (4)
Coronary Artery Bypass Graft Should Be Considered in Octogenarians With Multivessel Coronary Disease. (2016) (4)
A call for integrated foot care and amputation prevention pathways for patients with diabetes and peripheral arterial disease across Canada (2019) (4)
Regional health care services and rates of lower extremity amputation related to diabetes and peripheral artery disease: an ecological study. (2020) (4)
Lack of S 100 A 1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction (2009) (4)
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. (2022) (4)
CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. (2018) (4)
SGLT-2 Inhibitors and Regenerative Cell Exhaustion. (2020) (4)
When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease (4)
Antihyperglycemic agents and cardiovascular outcomes: recent insights (2017) (4)
Mitral valve repair with resection versus neochordae: A call for high-quality evidence. (2018) (4)
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults (2022) (4)
C-reactive protein and reendothelialization: NO involvement. (2007) (4)
Open or Endoscopic Vein Harvesting for Coronary-Artery Bypass Grafting. (2019) (4)
Fasting status and metabolic health in relation to plasma branched chain amino acid concentrations in women. (2020) (4)
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. (2022) (4)
Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression (2021) (3)
Failed Mitral TEER: Are There Lessons for Decision Making? (2021) (3)
A LEADER in the management of type 2 diabetes and cardiorenal disease. (2020) (3)
Mitral clip–looking back and moving forward (2016) (3)
Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes (2021) (3)
Trends in elective and ruptured abdominal aortic aneurysm repair by practice setting in Ontario, Canada, from 2003 to 2016: a population-based time-series analysis. (2019) (3)
The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients. (2012) (3)
Revascularization in left ventricular dysfunction: an update. (2019) (3)
156 Saphenous Vein Graft (SVG) Harvest Using Pedicled No-Touch Technique Limits Vascular Smooth Muscle Cell (VSMC) Activation - Results From The Patent SVG Study NCT01488084 (2012) (3)
BRCA2 is a Novel Regulator of Endothelial Cell Function and Apoptosis Following Oxidative Stress (2018) (3)
The impact of randomized trial results on abdominal aortic aneurysm repair rates from 2003 to 2016: A population-based time-series analysis (2019) (3)
The role of icosapent ethyl in cardiovascular risk reduction (2021) (3)
Abstract 14997: Icosapent Ethyl Reduces Ischemic Events in Patients With Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG (2020) (3)
Time to Remove the Left Atrial Appendage at Surgery: LAAOS III in Perspective. (2021) (3)
The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience (2017) (3)
Coronary Bypass Surgery for Diabetes and Multivessel Disease: Forget the SYNTAX. (2018) (3)
Optimizing cardiac cell therapy: from processing to delivery. (2005) (3)
The Morphology of Coronary Artery Disease in South Asians versus White Caucasians and its Implications. (2022) (3)
What is the state of hybrid coronary revascularization in 2018? (2018) (3)
HOMOGRAFT VERSUS CONVENTIONAL PROSTHESIS FOR SURGICAL MANAGEMENT OF AORTIC VALVE INFECTIVE ENDOCARDITIS A SYSTEMATIC REVIEW AND META-ANALYSIS (2017) (3)
The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction. (2020) (3)
TCT CONNECT-3 Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI (2020) (3)
Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. (2022) (3)
MOSES raises questions. (2006) (3)
Left main coronary stenosis: surgery still reigns (2017) (3)
Should patients with stable coronary artery disease be treated with ACE inhibitor therapy? (2005) (3)
Empagliflozin and Heart Failure. (2019) (3)
867-5 Rosiglitazone modulates angiogenic progenitor cell differentiation and attenuates intimal hyperplasia after vascular intervention (2004) (2)
Stage‐based approach to predict left ventricular reverse remodeling after mitral repair (2022) (2)
EMPEROR-Preserved: A promise fulfilled. (2021) (2)
Treatment of heart failure with sodium glucose co‐transporter‐2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions (2019) (2)
Year in review: mitral valve surgery (2016) (2)
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF (2022) (2)
Percutaneous management of coronary bifurcation lesions: current perspective. (2020) (2)
Revascularization strategies for left main coronary artery disease: current perspectives. (2020) (2)
Vascular Organoids: Are We Entering a New Area of Cardiometabolic Research? (2019) (2)
HIGH RATES OF CONCOMITANT ANTIPLATELET USE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULATION: INSIGHTS FROM THE STROKE PREVENTION AND RHYTHM INTERVENTIONS IN ATRIAL FIBRILLATION (SPRINT-AF) REGISTRY (2014) (2)
Is it time to REWIND the cardiorenal clock in diabetes? (2019) (2)
THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME (2019) (2)
Short-term outcomes of combined neuraxial and general anaesthesia versus general anaesthesia alone for elective open abdominal aortic aneurysm repair: retrospective population-based cohort study†. (2020) (2)
Impact of Empagliflozin on Left Ventricular Strain: Insights From the EMPA-HEART CardioLink-6 Randomized Clinical Trial. (2022) (2)
P1500Effects of empagliflozin on cardiac function in patients with type 2 diabetes mellitus: echocardiographic substudy of the EMPA-HEART cardiolink-6 trial (2019) (2)
Abstract 5356: Brca1 Is An Essential Regulator Of Cardiac Function (2008) (2)
Cardio-protective effects of sodium-glucose co-transporter 2 inhibitors: focus on heart failure. (2020) (2)
Antithrombotic therapy after transcatheter aortic valve replacement: current perspective. (2020) (2)
LINCRNA-P21 IS REGULATED BY CYCLIC MECHANICAL STRETCH AND UPREGULATED IN AORTIC ANEURYSMS (2017) (2)
Effects on duration of post-operative ischemia and patterns of blood flow recovery in different conditions of mouse hind limb ischemia (2011) (2)
Injection Drug Use Endocarditis: An Inner-City Hospital Experience (2021) (2)
The more you look, the more you find: atrial fibrillation – nowhere to hide (2019) (2)
Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. (2021) (2)
Response to G. J. Blake and P. M. Ridker: C-reactive protein: a surrogate risk marker or mediator of atherothrombosis? (2003) (2)
Human cardiac ischemia‐reperfusion injury: Blunted stress response with age (2021) (2)
Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide (2021) (2)
The Dance of 2 Devils: Mitral Valve Repair and Functional Mitral Stenosis. (2017) (2)
Geographic Variation in the Rates of Amputations Across Ontario: A Blueprint for Improvement (2018) (2)
Regulating Cardiac Energy Metabolism and Bioenergetics by Targeting the DNA Damage Repair Protein BRCA1 (2013) (2)
AJP MS # Revision 1 TRANSLATIONAL PHYSIOLOGY Angiotensin Converting Enzyme-2 (ACE2) confers endothelial protection and attenuates atherosclerosis (2008) (2)
Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial (2022) (2)
Revascularization for patients with diabetes mellitus and stable ischemic heart disease: an update (2017) (2)
Late reperfusion of a totally occluded infarct-related artery increases granulocyte-colony stimulation factor and reduces stroma-derived factor-1alpha blood levels in patients with ongoing ischemia after acute myocardial infarction. (2009) (2)
Survey of diabetes care in patients presenting with acute coronary syndromes in Canada. (2013) (2)
Mitral Arcades Unexpectedly Encountered During Cardiac Surgery. (2020) (2)
Resurgence of the edge-to-edge repair of the mitral valve. (2020) (2)
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses (2022) (2)
80-OR: Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis (2021) (1)
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved (2022) (1)
A genetic advance: lipoprotein(a) in aortic stenosis (2013) (1)
Aortic valve replacement with pulmonary hypertension: Meta‐analysis of 70 676 patients (2019) (1)
SOTAGLIFLOZIN REDUCES TOTAL HOSPITALIZATIONS AND INCREASES DAYS ALIVE AND OUT OF HOSPITAL IN THE SOLOIST-WHF TRIAL (2021) (1)
THE ASSOCIATION BETWEEN URIC ACID LEVELS AND CARDIORENAL OUTCOMES AND DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME (2019) (1)
CABG Versus PCI in Patients With Diabetes: A Meta-Analysis of Randomized Controlled Trials in the Era of Des (2013) (1)
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. (2022) (1)
Does C-reactive protein predict saphenous vein graft patency? (2007) (1)
Abstract 1478: Angiogenesis After a Myocardial Infarction is Regulated by Bone Marrow c-kit+ Cells (2006) (1)
Hope for Therapeutic Angiogenesis for Patients with Critical Limb Ischemia: From Bench to Bedside (2006) (1)
Restoration of Number and Function of Endothelial Progenitor Cells by Nocturnal Hemodialysis Is Associated with Normal Left Ventricular Geometry in Dialysis Patients.Dialysis Patients. (2004) (1)
The Impact of Statins on Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Outcomes: A Systematic Review and Meta-Analysis (2017) (1)
Restrictive versus liberal transfusion in patients with diabetes undergoing cardiac surgery: An open‐label, randomized, blinded outcome evaluation trial (2021) (1)
VALPROIC ACID INDUCES ENDOTHELIAL-TO-MESENCHYMAL-LIKE PHENOTYPIC SWITCHING (2016) (1)
56The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension (2019) (1)
Abstract 18789: BRCA2 is a Novel Regulator of Endothelial Cell Function and Apoptosis Following Hyperglycemia (2015) (1)
Abstract 18705: BRCA2 is a Novel Regulator of Endothelial Cell Function and Apoptosis (2015) (1)
The year in cardiovascular medicine 2021: diabetes and metabolic disorders. (2022) (1)
019 Who receives asa for primary prevention in canada?: Insight from the primary care audit of global risk management (PARADIGM) study (2011) (1)
DUAL ANTI-PLATELET THERAPY IS NOT SUPERIOR TO ASPIRIN ALONE AFTER CORONARY ARTERY BYPASS IN DIABETIC PATIENTS WITH MULTI-VESSEL DISEASE: INSIGHTS FROM THE FREEDOM TRIAL (2016) (1)
Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial (2018) (1)
P3753Does empagliflozin modulate the autonomic system among patients with type 2 diabetes and coronary artery disease? Insights from the Holter sub-study of the EMPA-Heart CardioLink-6 Randomised Trial (2019) (1)
THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS LIRAGLUTIDE AND SEMAGLUTIDE IMPROVE CARDIOVASCULAR AND RENAL OUTCOMES ACROSS BASELINE BLOOD PRESSURE CATEGORIES: ANALYSIS OF LEADER AND SUSTAIN 6 (2018) (1)
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. (2022) (1)
Audit of cardiovascular risk assessment and lipid management by Canadian primary care physicians (2016) (1)
Dealing with the epidemic of endocarditis in people who inject drugs. (2022) (1)
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? (2017) (1)
Expression in Human Endothelial Cells C-Reactive Protein Upregulates Receptor for Advanced Glycation End Products (2006) (1)
Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial (2022) (1)
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2022) (1)
Abstract 10824: A Novel Role of Endothelial Autophagy in the Regulation of Thrombosis in vivo (2015) (1)
MS09.2 Empagliflozin Reduces Mortality In Patients With Type 2 Diabetes and A History of Left Ventricular Hypertrophy: A Sub-analysis of the EMPA-REG OUTCOME Trial (2018) (1)
Cardiovascular Protection in People With Diabetes Diabetes Canada Clinical Practice Guidelines Expert Committee (2018) (1)
Abstract 11544: MicroRNA-145 Targeted Therapy Reduces Atherosclerosis and Improves Plaque Stability (2011) (1)
THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES MORTALITY IN EXPERIMENTAL PULMONARY HYPERTENSION (2019) (1)
Stuck Between a Rock and a Hard Place: The Clinical Conundrum of Managing Cardiac Surgical Patients During the SARS-CoV-2 Pandemic (2021) (1)
Acetylsalicylic acid use in primary prevention in Canada: Insight from the Primary Care Audit of Global Risk Management (PARADIGM) study (2016) (1)
GENDER-RELATED DIFFERENCES IN CARDIOVASCULAR RISK ASSESSMENT AND MANAGEMENT IN PRIMARY CARE: INSIGHTS FROM THE PARADIGM STUDY (2014) (1)
391 Prevalence of Risk Factors and Occult Coronary Disease in South Asians Referred to a Specialized Risk Assessment Clinic (2012) (1)
Cyclosporin induced endothelial dysfunction: effects of the nitric oxide cofactor, tetrahydrobiopterin (2002) (1)
Knowledge and attitudes of Canadian cardiac surgeons regarding patients with human immunodeficiency virus. (2020) (1)
A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. (2008) (1)
Exploring the Clinical Implications of Wnt Signaling in Enucleated Erythrocytes. (2021) (1)
THE IMPACT OF ARNI THERAPY ON LV SYSTOLIC FUNCTION AS MEASURED BY 2-D ECHOCARDIOGRAPHY: A 1 YEAR CASE SERIES (2017) (1)
SIGNIFICANT CARDIOVASCULAR BENEFITS OF ICOSAPENT ETHYL FROM REDUCE-IT (2020) (1)
Isolation and characterization of circulating pro-vascular progenitor cell subsets from human whole blood samples (2021) (1)
Abstract 9164: Who Receives ASA for Primary Prevention in Canada?: Insight From the PRIMARY CARE AUDIT OF GLOBAL RISK MANAGEMENT (PARADIGM) Study (2011) (1)
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock (2022) (1)
Does Interleukin-17A Blockade Have a Potential Clinical Role to Reduce Cardiovascular Risk in Psoriasis? (2020) (1)
APPLYING REWIND CVD CRITERIA TO SUSTAIN 6 AND PIONEER 6: AN EXPLORATORY ANALYSIS OF CV OUTCOMES WITH SEMAGLUTIDE (2020) (1)
Non-infarct related artery revascularization in ST-segment elevation myocardial infarction patients with multivessel disease (2017) (1)
Outcomes of Abdominal Aortic Aneurysm Repair Among Patients with Rheumatoid Arthritis. (2020) (1)
P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists (2017) (1)
INNOMINATE ARTERY CANNULATION PROVIDES SIMILAR NEUROPROTECTION TO AXILLARY CANNULATION IN AORTIC ARCH SURGERY AND MAY REDUCE OPERATIVE TIMES (2014) (1)
386 Prevalence of Impaired Fasting Glucose in Healthy Middle-Aged Adults: Insights from the Primary Care Audit of Global Risk Management (PARADIGM) Study (2012) (1)
APPLICATION OF THE TIMI HEART FAILURE RISK SCORE TO THE EMPA-REG OUTCOME POPULATION (2020) (1)
Abstract 2331: BRCA1 Limits Inflammation Induced Apoptosis And Improves Endothelial Function: A Novel Role Of DNA Repair Genes In Vascular Homeostasis (2008) (1)
113 Gene therapy with brca1 reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis (2011) (1)
28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME (2020) (1)
Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 months in a Randomized Trial. (2022) (1)
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME (2020) (1)
Acute Infarcts on Brain MRI Following Aortic Arch Repair With Circulatory Arrest: Insights From the ACE CardioLink-3 Randomized Trial (2022) (1)
CANADIAN SOCIETY FOR VASCULAR SURGERY (2018) (1)
Society Guidelines Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease (2014) (1)
AJP: Regulatory, Integrative and Comparative Physiology 1 TETRAHYDROBIOPTERIN DEFICIENCY EXAGGERATES INTIMAL HYPERPLASIAAFTER VASCULAR INJURY (2005) (0)
What's hot in heart valve disease 2017? (2017) (0)
82-LB: Total Costs of Care in Patients with T2D and Cardiovascular Disease: A Comparative Cohort Study (OFFSET) (2021) (0)
SODIUM-GLUCOSE CO-TRANSPORTER INHIBITORS AND ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2021) (0)
728 BRCA1 induces cardiac protection through a P53-dependent pathway (2011) (0)
ESM August 2002 (2002) (0)
Abstract 13456: The Effect of Empagliflozin on Myocardial Extracellular Matrix Expansion in Patients With Type 2 Diabetes and Coronary Artery Disease (2019) (0)
CONTEMPORARY MANAGEMENT AND CONTROL OF UNCOMPLICATED HYPERTENSION: INSIGHTS FROM THE PRIMARY CARE AUDIT OF GLOBAL RISK MANAGEMENT (PARADIGM) STUDY (2012) (0)
DIFFICULT TO TREAT HYPERTENSIVE PATIENTS WITH NOCTURNAL ELEVATION OF BLOOD PRESSURE HAVE A HIGH PROBABILITY OF OBSTRUCTIVE SLEEP APNEA (2019) (0)
N003 Implementation of the New Nurse Practitioner (NP) Authorities to Optimize Care and Patient Flow for Cardiovascular Surgical Patients (2012) (0)
MS03.2 Peripheral Artery Disease and Diabetes-related Amputations: Temporal Trends and Geographic Variation (2018) (0)
A genetic advance: lipoprotein(a) in aortic (2013) (0)
Abstract 11922: Adiponectin Limits Monocytic Microparticle-Induced Inflammasome Activation and Endothelial Dysfunction (2014) (0)
TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL (2021) (0)
Author response for "Prediction of Heart Failure Outcomes in Patients with Type 2 Diabetes Mellitus: Validation of the TRS‐HF DM Score in the ACCORD Trial" (2020) (0)
aortic valves? Can statin therapy alter the natural history of bicuspid (2016) (0)
Multimodality imaging for resuscitated sudden cardiac death. (2015) (0)
The Impact of Statins on Postdischarge Atrial Fibrillation After Cardiac Surgery: Secondary Analysis from a Randomized Trial (2022) (0)
EFFICACY AND SAFETY OF EMPAGLIFLOZIN ACCORDING TO BACKGROUND DIURETIC USE IN PATIENTS WITH HEART FAILURE AND A REDUCED EJECTION FRACTION: A SUB-ANALYSIS OF THE EMPEROR-REDUCED CLINICAL TRIAL (2023) (0)
100 Prolonged cardiovascular system failure in South Asians undergoing cardiopulmonary bypass correlates with prolonged inflammation and increased TLR4-mediated signaling (2011) (0)
Abstract 12428: Efficacy of a Risk Reduction Program to Improve Cardiovascular Outcomes in Patients With Peripheral Arterial Disease: A Propensity Score-Matched Study (2015) (0)
EFFECTS OF EMPAGLIFLOZIN ON DIASTOLIC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (2019) (0)
P317A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study of the EMPA-HEART CardioLink-6 Trial (2019) (0)
Abstract 14502: Variability in Traditional and Novel Cardiovascular Risk Factors by Ethnic Origin: Insights from the Primary Care Audit of Global Risk Management (PARADIGM) Study (2012) (0)
ENDOTHELIAL PRIMARY CILIA INHIBITS THROMBOSIS (2016) (0)
Skeletonized internal thoracic arteries for CABG surgery: a new gold standard? (2007) (0)
Discussion on Key Heart Failure Risk Factors in Patients With Type 2 Diabetes Mellitus (2020) (0)
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG (2016) (0)
ENDOTHELIAL AUTOPHAGY IS ESSENTIAL FOR VASCULAR LIPID HOMEOSTASIS (2015) (0)
Abstract 3695: BRCA1 is a Novel Modulator of Cardiac Substrate Metabolism and Restores Cardiac Function in Response to Ischemic and Genotoxic Stressors (2009) (0)
ADIPONECTIN LIMITS MONOCYTIC MICROPARTICLE-INDUCED INFLAMMASOME ACTIVATION AND ENDOTHELIAL DYSFUNCTION (2014) (0)
THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME (2020) (0)
Abstract 11493: Gene Therapy with BRCA1 Reduces Systemic Inflammatory Response and Multiple Organ Failure and Improves Survival in Experimental Sepsis (2011) (0)
Risk Factors for Post-Repair Elevated Mitral Gradient: A Post-Hoc Analysis of a Randomized Trial. (2022) (0)
IMPROVEMENT OF THE 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK WITH ONCE-WEEKLY SEMAGLUTIDE 2.4 MG IN ADULTS WITH OVERWEIGHT OR OBESITY - POST-HOC ANALYSIS OF THE STEP 1 TRIAL (2021) (0)
Abstract 15196: Autophagy Regulates Vascular Smooth Muscle Cell Phenotypic Switching: Translational Implications for Aneurysm Formation (2013) (0)
Complete transcatheter versus complete surgical management for combined aortic stenosis and coronary artery disease: A false dichotomy? (2022) (0)
Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial (2022) (0)
Aortic valve neocuspidization and its technical nuance (2022) (0)
The Role of Autophagy in Vascular Biology in Vascular (2015) (0)
018 Contemporary trends in hypertension in canada: Insight from the primary care audit of global risk management (paradigm) study (2011) (0)
Population‐Based Secular Trends in Lower Extremity Amputations for Diabetes and Peripheral Artery Disease: IP215. (2018) (0)
The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF) (2021) (0)
Abstract 444: Absence of S100A1 in Mice is Associated With a Hypertensive Phenotype Dependent on Both Gender and Endothelial Function (2007) (0)
4D FLOW MRI IDENTIFIES REGIONS OF MORE SEVERE AORTOPATHY IN THE HUMAN BICUSPID AORTA (2015) (0)
Endothelial long non-coding RNAs regulated by oxidized LDL (2017) (0)
KNOWLEDGE, ATTITUDES AND PRACTICE PATTERNS OF CANADIAN CARDIAC SURGEONS REGARDING PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (2019) (0)
URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME (2019) (0)
REGENERATIVE CELL EXHAUSTION AND CARDIOVASCULAR RISK IN SOUTH ASIANS: A PILOT STUDY (2023) (0)
Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus (2016) (0)
88 - Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: LEADER and SUSTAIN 6 (2019) (0)
Characteristics of Non-Diabetic Middle-Aged Adults With Chronic Kidney Disease (CKD) - Insight From the Paradigm Registry (2013) (0)
Incidence, predictors, and impact of bioprosthesis valve hemodynamic deterioration following aortic valve replacement (2018) (0)
A SYSTEMATIC REVIEW AND META-ANALYSIS OF 45 RANDOMIZED STUDIES USING PROTOCOL-DRIVEN ASSESSMENT OF SAPHENOUS VEIN GRAFT PATENCY (2020) (0)
Deciphering the ARB and MI Data: Insight from Systematic Reviews, Meta-analyses, Meta-regression Analyses, and Non-Inferiority Trials (2017) (0)
ENDOTHELIAL-SPECIFIC LOSS OF AUTOPHAGY PROMOTES ORGAN FIBROSIS (2015) (0)
L-arginine protects human heart cells from simulated anoxia and reoxgenation (2002) (0)
708 Microrna-145 is a novel regulator of atherosclerosis and plaque stability (2011) (0)
An Arrow Through the Heart. (2022) (0)
Thirty-day hospital readmission and emergency department visits after vascular surgery: a Canadian prospective cohort study. (2018) (0)
Abstract 11502: Cardiac-Specific Disruption of BRCA2 Results in Higher Doxorubicin Sensitivity and Heart Failure with Advanced Age (2011) (0)
Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. (2020) (0)
SELECTIVE DELETION OF ENDOTHELIAL AUTOPHAGY RELATED 7 (ATG7) INHIBITS THROMBUS FORMATION IN MICE (2016) (0)
Endothelial Progenitor Cells New Hope for a Broken Heart Brief Review: From Bench to Bedside (2003) (0)
CONTINUED TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO SUSTAINED IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 4 TRIAL (2021) (0)
Empagliflozin restores the integrity of the endothelial glycocalyx in vitro (2019) (0)
Author response for "The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of LEADER and SUSTAIN 6 trials" (2020) (0)
Abstract 13767: BRCA1 Reduces Oxidative Stress, Up-Regulates Nitric Oxide Production, and Attenuates Endothelial Cell Apoptosis: A Novel Target for Reduced Endothelial Dysfunction (2012) (0)
P1267Empagliflozin prevention of heart failure development in diabetes is associated with an improvement in cardiac energy producition (2018) (0)
C-reactive protein and atherothrombosis-beyond a biomarker: an actual partaker of lesion formation. Authors' reply (2003) (0)
C-reactive protein activates the NF-κB signal transduction pathway in human saphenous vein endothelial cells (2003) (0)
Glycemic Management in Patients Presenting with Acute Coronary Syndromes: Survey of Care by Canadian Endocrinologists and Cardiologists (2012) (0)
Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. (2020) (0)
Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle (2003) (0)
ARB & Renal Protection: A Response to Dr. Opie (2017) (0)
Abstract 11527: Prolonged Cardiovascular System Failure in South Asians Undergoing Cardiopulmonary Bypass Correlates with Prolonged Inflammation and Increased TLR4-Mediated Signaling (2011) (0)
IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial. (2023) (0)
Factor XI inhibitors: what should clinicians know (2022) (0)
IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN-6 CLINICAL TRIALS (2019) (0)
Abstract 11488: MicroRNA-141 is a Novel Regulator of BMP-2-Mediated Calcification in Aortic Stenosis (2011) (0)
A GLOBAL PROFILE OF GLUCOSE-SENSITIVE ENDOTHELIAL-EXPRESSED LONG NON-CODING RNAS (2016) (0)
Draft 1 A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs (2016) (0)
Abstract 13928: Adropin is a Novel Regulator of Endothelial Function Through the VEGFR2- PI3K-Akt and VEGFR2- Erk1/2 Pathways (2010) (0)
RESECTION MITRAL VALVE REPAIR WITH SMALL ANNULOPLASTY IS AT HIGHER RISK OF FUNCTIONAL MITRAL STENOSIS (2022) (0)
Abstract 12722: CABG Versus PCI in Patients with Diabetes: A Metaanalysis of Randomized Controlled Trials in the Era of Stents (2013) (0)
Combined Neuraxial and General Anesthesia Significantly Improves Perioperative Outcomes Following Elective Open Abdominal Aortic Aneurysm Repair (2019) (0)
Angiotensin receptor blockers and myocardial infarction (2005) (0)
Abstract 12721: Brca1 Protects Vascular Smooth Muscle Cells from Oxidative Stress and Reduces Blood Pressure (2013) (0)
What's hot in heart valve disease 2018? (2018) (0)
Management of Less-Than-Severe Aortic Stenosis During Coronary Bypass: A Systematic Review and Meta-Analysis (2019) (0)
THE INFLUENCE OF STROKE AND BLEEDING RISK ON ORAL ANTICOAGULATION USE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE STROKE PREVENTION AND RHYTHM INTERVENTIONS IN ATRIAL FIBRILLATION (SPRINT-AF) REGISTRY (2014) (0)
Abstract 11116: Prevalence of Impaired Fasting Glucose in Healthy Middle-Aged Adults: Insights from the Primary Care Audit of Global Risk Management (PARADIGM) Study (2012) (0)
A Response To Dr. E. Lewis (2017) (0)
Abstract 14962: Empagliflozin’s Cardiovascular Impact in High-Risk Patients With Type 2 Diabetes and Obstructive Pulmonary Disease: An Inquiry From EMPA-REG OUTCOME (2020) (0)
MITRAL VALVE REPAIR WITH LEAFLET PRESERVATION VS. LEAFLET RESECTION AND VENTRICULAR REMODELING - A SUB-ANALYSIS OF THE RANDOMIZED CAMRA STUDY - (2021) (0)
Effect of Operator Specialty on the Outcomes of Carotid Artery Revascularization: VESS02. (2017) (0)
SHOULD DUAL ANTIPLATELET THERAPY BE USED AFTER CORONARY ARTERY BYPASS SURGERY? A META-ANALYSIS OF 4662 PATIENTS FROM RANDOMIZED CONTROLLED TRIALS (2014) (0)
EFFICACY OF EMPAGLIFLOZIN IN HEART FAILURE PATIENTS WITH A HISTORY OF PERIPHERAL ARTERIAL DISEASE: ANALYSIS FROM EMPEROR-POOLED (2023) (0)
ATG7-SILENCING INDUCES ENDOTHELIAL-MESENCHYMAL TRANSITION-LIKE PHENOTYPIC SWITCHING IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (2014) (0)
DUAL ANTIPLATELET THERAPY AND SURGICAL REVASCULARIZATION: A SURVEY OF CANADIAN CARDIAC SURGEONS (2015) (0)
A NOVEL ROLE OF SGLT2 INHIBITORS TO INCREASE CIRCULATING PROANGIOGENIC PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE: A SUB-STUDY OF THE EMPA-HEART CARDIOLINK-6 TRIAL (2019) (0)
ENDOTHELIAL AUTOPHAGY REGULATES ARTERIAL THROMBUS FORMATION IN MICE (2015) (0)
787 Snapshot of Glycemic Management in Patients Presenting With Acute Coronary Syndromes: Survey of Care by Cardiologists and Endocrinologists Across Canada (2012) (0)
Insulin and the Heart (1999) (0)
Response to Verma et al (2006) (0)
Abstract 15572: BRCA1 is a Novel Regulator of Vascular Smooth Muscle Phenotypic Modulation and a Target for Blood Pressure Regulation and Vascular Remodeling (2012) (0)
LIRAGLUTIDE REDUCES CARDIOVASCULAR EVENTS AND MORTALITY IN TYPE 2 DIABETES INDEPENDENT OF LDL CHOLESTEROL AND STATIN USE: RESULTS OF THE LEADER TRIAL (2018) (0)
Moving Beyond Beta-Blockers and Amiodarone: The Use of Anti-Inflammatories to Treat Post-Cardiac Surgery Atrial Fibrillation. (2016) (0)
Abstract 6255: Adiponectin Deficiency Profoundly Exacerbates Sepsis-Related Mortality through Endothelial Activation: A Novel Mechanistic Link between Adiposity and Sepsis (2008) (0)
Stuck between a rock and a hard place: The clinical conundrum of managing cardiac surgical patients during the SARS‐CoV‐2 pandemic (2021) (0)
Adherence to Evidence-Based Medications in South Asian and White Caucasian Patients With Coronary Heart Disease - Insight From the Practice Registry (2013) (0)
Issue Information Page (2020) (0)
Abstract 14667: Endothelial-specific Loss of Primary Cilia Exacerbates Cardiac Fibrosis (2016) (0)
Special Article Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications (2013) (0)
Bosentan: a therapeutic strategy for severe radial artery vasospasm (2002) (0)
C-Reactive Protein Attenuates Endothelial Progenitor Cell Survival, Differentiation, and Function Further Evidence of a Mechanistic Link Between C-Reactive Protein and Cardiovascular Disease Clinical Investigation and Reports (2004) (0)
084 Alterations in cardiac brca1 expression in human models of ischemia (2011) (0)
A cross‐sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa (PACT‐MEA): Study design and rationale (2023) (0)
LONG-TERM OUTCOMES OF CAROTID SURGERY VERSUS STENTING IN ONTARIO: A POPULATION-BASED ANALYSIS (2016) (0)
Age‐ and Sex‐Stratified Trends in Elective and Ruptured Abdominal Aortic Aneurysm Repair from 2003 to 2016 (2018) (0)
Long-Term Health Care Costs in Patients with Diabetes or Peripheral Arterial Disease Who Require Lower Extremity Amputation: A Population-Based Analysis (2019) (0)
IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN 6 CLINICAL TRIALS (2019) (0)
Painful legs, aching heart: Reducing cardiovascular risk in patients with peripheral arterial disease with angiotensin-converting enzyme inhibition. (2005) (0)
Abstract 19506: The Differential Effects of Valsartan/Sacubirtril on Cardiac Function in Ischemic versus Dilated Cardiomyopathy: A 1 Year Real World Study (2017) (0)
ENDOTHELIAL AUTOPHAGY REGULATES CHOLESTEROL TRANSPORT AND IS A NOVEL REGULATOR OF ATHEROSCLEROSIS (2014) (0)
Impact of diabetes and glucose-lowering therapy on post-operative atrial fibrillation after cardiac surgery: secondary analysis of the SEARCH-AF CardioLink-1 randomized clinical trial (2022) (0)
Abstract 14897: Statins Reduce Periprocedural and Long-term Risks of Stroke and Death After Carotid Artery Revascularization (2017) (0)
Abstract 16946: Accuracy of Cardiovascular (cv) Risk Stratification by Canadian Primary Care Physicians: Preliminary Results From the Primary Care Audit of Global Risk Management (PARADIGM) Study (2010) (0)
An Essential Role of Autophagy in Vascular Smooth Muscle Cell Homeostasis (2013) (0)
Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling. (2023) (0)
SCARF: SAXAGLIPTIN AND CARDIAC STRUCTURE AND FUNCTION (2019) (0)
Clinical guidelines and the evolving approaches to bicuspid aortopathy (2016) (0)
Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization: PC062. (2018) (0)
Abstract 298: Effects of Long-Term Autophagy Inhibition With Chloroquine on the Development and Progression of Experimental Abdominal Aortic Aneurysms (2014) (0)
Impact of diabetes duration on left ventricular mass regression with empagliflozin. (2023) (0)
A novel algorithm for rapid sequence optimization of guideline directed medical therapy for heart failure with reduced ejection fraction (2022) (0)
Fingerprint of long non-coding RNA regulated by cyclic mechanical stretch in human aortic smooth muscle cells: implications for hypertension (2017) (0)
Carotid Artery Revascularization: Does Surgeon or Interventionalist Specialty Matter? (2017) (0)
497 BRCA1 Limits AT1-Mediated Redox Signaling, Improves Vascular Reactivity and Reduces Blood Pressure in Spontaneously Hypertensive Rats (2012) (0)
711 Novel gene expression changes in bicuspid aortic valves (2011) (0)
S37-1 C-REACTIVE PROTEIN IN ATHEROSCLEROSIS (2007) (0)
Response by Bagai et al to Letter Regarding Article, "Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention". (2016) (0)
Bentracimab for Ticagrelor Reversal in Patients (2021) (0)
Editorial. To pace or not to pace: that is the question. (2017) (0)
Author response for "Cardiometabolic Risk Factor Control in African American and White Caucasians initiating SGLT ‐2 Inhibitor: Real‐world Study" (2020) (0)
INCIDENCE, PREDICTORS, AND IMPACT OF BIOPROSTHETIC VALVE HEMODYNAMIC DETERIORATION FOLLOWING AORTIC VALVE REPLACEMENT (2017) (0)
The Effect of Renin-Angiotensin System Blockade on Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Outcomes: A Systematic Review and Meta-Analysis (2017) (0)
Quantifying von Willebrand Factor (VWF) degradation during continuous LVAD support. (2020) (0)
CARDIOVASCULAR (CV) RISK STRATIFICATION BY PRIMARY CARE PHYSICIANS (PCPS) USING FRAMINGHAM RISK SCORE (FRS) AND IN-OFFICE CAROTID ULTRASOUND: PRELIMINARY RESULTS FROM THE PRIMARY CARE AUDIT OF GLOBAL RISK MANAGEMENT (PARADIGM) STUDY (2011) (0)
The Fall of Carotid Endarterectomy and Rise of Carotid Artery Stenting in Ontario from 2002 to 2014 (2016) (0)
208 Adiponectin Inhibits Endothelial Microparticle Generation: A Novel Mechanism Of Endothelial Protection (2012) (0)
Investigation of novel LPS-induced differentially expressed long non-coding RNAs in endothelial cells (2016) (0)
When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease. (2021) (0)
701 Cardiac-specific disruption of BRCA2 results in higher doxorubicin sensitivity and heart failure with advanced age (2011) (0)
EFFECT OF CLINICAL TRIAL PUBLICATIONS ON TRENDS IN CAROTID SURGERY AND STENTING IN ONTARIO FROM 2002 THROUGH 2014 (2016) (0)
Pedicled 'No-Touch' Saphenous Vein Graft Harvest Limits Vascular Smooth Muscle Cell Activation - the Patent Svg Study (NCT01488084) (2013) (0)
Abstract 17195: Raas Modulation Through ARNI Therapy but Not ACE-Inhibitor Therapy Improves Cardiac Systolic Function and Cardiac Aerobic Functional Capacity in Patients With HFrEF (2019) (0)
C-Reactive Protein and Reendothelialization (2007) (0)
C-Reactive Protein Structure Affects Function Focused Perspective (2004) (0)
Chronic heart failure management in adult patients with congenital heart disease (2023) (0)
P5602Comparison of innominate vs axillary artery cannulation for cerebral protection on neurocognitive outcomes in aortic surgery: a pre-specified analysis of the ACE CardioLink-3 randomised trial (2019) (0)
Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME (2020) (0)
P2858Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial (2018) (0)
THE ASSOCIATION BETWEEN ANTHROPOMETRIC MEASURES OF OBESITY AND LEFT VENTRICULAR REVERSE REMODELLING WITH EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND CORONARY ARTERY DISEASE: A SUB ANALYSIS OF THE EMPA-HEART CARDIOLINK-6 TRIAL (2023) (0)
Efficacy of a Risk Reduction Program to Improve Cardiovascular Outcomes in Patients With Peripheral Arterial Disease: A Propensity Score-Matched Study (2015) (0)
Transfusion Thresholds for Acute Coronary Syndromes—Insights From the TRICS‐III Randomized Controlled Trial, Systematic Review, and Meta‐Analysis (2022) (0)
Human Cardiac Ischemia-Reperfusion Injury: Blunted Stress Response with Age (0)
Treatment With Once-weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults With Overweight or Obesity and Type 2 Diabetes: STEP 2 Post Hoc Analysis (2022) (0)
The impact of statin on post-operative atrial fibrillation after discharge from cardiac surgery: secondary analysis of the SEARCH-AF CardioLink-1 randomized trial (2022) (0)
Modulation of atrial electrophysiology and oxidative stress by the endogenous peptide hormone apelin: implications in human atrial fibrillation (2011) (0)
EMPAGLIFLOZIN REDUCED CIRCULATING PRO-INFLAMMATORY PRECURSOR CELL CONTENT IN PEOPLE WITHOUT DIABETES: A SUBSTUDY OF THE EMPA-HEART 2 CARDIOLINK 6 TRIAL (2023) (0)
Age period cohort analysis of rheumatic heart disease in high-income countriess. (2023) (0)
Cardiovascular inflammation is reduced with methotrexate in diabetes (2017) (0)
Valvular surgery is associated with an increased risk of post-operative atrial fibrillation: secondary analysis of the SEARCH-AF CardioLink-1 randomized trial (2022) (0)
Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction. (2023) (0)
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause (2022) (0)
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial (2022) (0)
Clinical trials in valvular surgery: a 2018 update (2017) (0)
Differential Effects of Autophagy in Macro- and Microvascular Endothelial Cells Drives Small Vessel Muscularization in Pulmonary Hypertension (2019) (0)
Abstract 4746: Adropin is a Novel and Potent Endogenous Angiogenic Neuroendocrine Peptide (2009) (0)
ESICON 2019 Abstracts (2019) (0)
Hospital Readmission and Emergency Department Visits After Vascular Surgery: A Prospective Cohort Study (2017) (0)
Adiponectin Limits Microparticle-Induced Endothelial Dysfunction (2013) (0)
530 BRCA1 is a Novel Molecular Target to Limit Pancreatic Beta Cell Apoptosis and Restore Beta Cell Function (2012) (0)
MS02.8 Economic and Clinical Burden of Diabetic Foot Ulcers: A Multicentre Study (2018) (0)
Abstract 11516: BRCA1 Induces Cardiac Protection Through a P53-Dependent Pathway (2011) (0)
C-reactive protein: a surrogate risk marker or mediator of atherothrombosis? Authors' reply (2003) (0)
SURGICAL AND PHARMACOLOGICAL NOVEL INTERVENTIONS TO IMPROVE SAPHENOUS VEIN GRAFT PATENCY IN CORONARY ARTERY BYPASS GRAFTING SURGERY: AN INTERNATIONAL MULTI-CENTRE RANDOMIZED CONTROLLED CLINICAL TRIAL (SUPERIOR SVG STUDY) (2017) (0)
Abstract 12302: A Novel Role of Autophagy in the Regulation of Endothelial to Mesenchymal Transition (2014) (0)
Lower Limb Amputations in Patients With Diabetes and Peripheral Artery Disease: A Time‐Series Analysis of Trends (2005‐2016) (2018) (0)
COMPARATIVE EVALUATION OF ADIPOKINES, INFLAMMATORY MARKERS AND CARDIOVASCULAR OUTCOMES IN ASIAN INDIANS VS. EUROPEAN WHITES WITH CORONARY HEART DISEASE: RESULTS FROM THE PRACTICE REGISTRY (2011) (0)
Abstract 11456: Liraglutide and Semaglutide Reduce Cardiovascular Events in Patients With Type 2 Diabetes and Peripheral Arterial Disease (2019) (0)
Assessment and management of coronary artery disease in patients undergoing transcatheter aortic valve replacement. (2020) (0)
Impact of Statins on Clinical Outcomes After Carotid Endarterectomy and Stenting: A Population‐Based Cohort Study (2018) (0)
406-2 Stem cell factor plays a critical role in neointimal formation by bone marrow derived progenitor cells (2004) (0)
Abstract 13814: Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials (2020) (0)
A randomized surgical trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis – primary results of the CAMRA CardioLink-2 trial (2020) (0)
Abstract 15379: Regulation of Long Non-Coding RNA Fingerprint by Cyclic Mechanical Stretch in Vascular Smooth Muscle Cells: Implications for Aortic Aneurysms (2016) (0)
P1266Empagliflozin improves left ventricular diastolic function in db/db mice without altering cardiac expression of enzymes relevant for ketone body or branched chain amino acid catabolism (2018) (0)
Abstract 1566: Adiponectin Primes Human Monocytes Into Alternative M2 Macrophages With Anti-inflammatory Properties: A Novel Mechanism of Obesity Induced Atherosclerosis (2009) (0)
HEART FAILURE OUTCOMES IN PATIENTS WITH DIABETES WITH AND WITHOUT ATRIAL FIBRILLATION - DATA FROM THE EMPA-REG OUTCOME STUDY (2019) (0)
Abstract 1188: Prognostic Significance of Markers of Vascular Health: Long-term Results From the Firefighters And Their Endothelium (FATE) Study (2009) (0)
THE IMPACT OF A COMPREHENSIVE HEART FAILURE MANAGEMENT PROGRAM INCLUDING PHARMACOLOGICAL OPTIMIZATION WITH VALSARTAN/SACUBITRIL ON CARDIAC FUNCTION AND FUNCTIONAL CAPACITY IN REDUCED EJECTION FRACTION HEART FAILURE (2019) (0)
Electrophysiology Study and Catheter Ablation With Superior Vena Cava Stump. (2017) (0)
Brca1 Protects Vsmc From Oxidative Stress and Reduces Blood Pressure in Spontaneously Hypertensive Rats (2013) (0)
Abstract 18898: Long Non-coding RNA Fingerprint Regulated by Stretch and Cyclic Strain in Vascular Smooth Muscle Cells: Implications for Aortic Aneurysms (2015) (0)
Abstract 14961: External Applicability of REDUCE-IT in a Large Diabetes Cardiovascular Outcomes Trial: A Post Hoc Analysis of EMPA-REG OUTCOME (2020) (0)
A novel technique to assess flow-mediated vasodilation. (2004) (0)
Long-term Outcomes of Carotid Endarterectomy Versus Stenting: A 12-Year Multicenter Observational Analysis of 14,464 Patients (2016) (0)
Novel cardioprotective effects of tetrahydrobiopterin (BH4) following ischemia reperfusion (I/R) (2001) (0)
Abstract 20383: Incidence, Predictors, and Impact of Bioprosthetic Valve Hemodynamic Deterioration Following Aortic Valve Replacement (2017) (0)
Abstract 13974: Loss of Endothelial Primary Cilia Promotes Thrombus Formation in Mice (2016) (0)
FACTORS ASSOCIATED WITH NEW ORAL ANTICOAGULANT VERSUS VITAMIN K ANTAGONIST USE IN A CONTEMPORARY, NATIONAL, REAL-WORLD OBSERVATIONAL REGISTRY: INSIGHTS FROM THE STROKE PREVENTION AND RHYTHM INTERVENTIONS IN ATRIAL FIBRILLATION (SPRINT-AF) REGISTRY (2014) (0)
Abstract 13947: Targeting DNA Repair to Prevent Athracycline-induced Cardiac Failure (2010) (0)
Abstract 11917: Effects of Long Term Autophagy Inhibition With Chloroquine on the Development and Progression of Experimental Abdominal Aortic Aneurysms (2014) (0)
LOSS OF ENDOTHELIAL CELL-SPECIFIC INTRAFLAGELLAR TRANSPORT PROTEIN 88 ENHANCES DOXORUBICIN-INDUCED CARDIOTOXICITY-RELATED PHENOTYPES (2019) (0)
Ticagrelor Use and Practice Pattern among Canadian Cardiac Surgeons (2021) (0)
Bacteriological profile of neonatal sepsis by blood culture: A prospective study in a tertiary care center of north India (2019) (0)
ADIPONECTIN REGULATES MONOCYTE MICROPARTICLE PRODUCTION AND ENDOTHELIAL ACTIVATION (2015) (0)
ACEI vs ARB - A response to the trialist's perspective (2017) (0)
Should functional assessment of lesion severity be used to guide coronary bypass? (2018) (0)
IMPACT OF DIABETES ON CAROTID ARTERY REVASCULARIZATION: A SYSTEMATIC REVIEW AND META-ANALYSIS (2015) (0)
HEPATIC FAT CHANGES AFTER AN ANTISENSE OLIGONUCLEOTIDE THERAPY TARGETING ANGPTL3: A TRANSLATE-TIMI 70 ANALYSIS (2023) (0)
Transcatheter aortic valve implantation for severe aortic stenosis (2019) (0)
Risk of Intracranial Hemorrhage After Carotid Endarterectomy Versus Stenting (2017) (0)
Making for Endovascular Repair of Abdominal Aortic Aneurysm (2004) (0)
Re: Endothelin antagonism and internal mammary artery endothelial function (2001) (0)
PCSK9 INHIBITION: REAL WORLD APPLICATION AND CHALLENGES TO ACHIEVE UNMET CHOLESTEROL TARGETS IN CANADIAN ATHEROSCLEROTIC HEART DISEASE, THE PRACTICAL STUDY (2018) (0)
Predictors of mitral valve haemodynamics after mitral valve repair for degenerative mitral regurgitation (2023) (0)
020 Prevalence of risk factors and occult coronary disease in south asians referred to a specialized risk assessment clinic (2011) (0)
Heart valve disease: looking back and moving forward. (2016) (0)
SEX DIFFERENCES IN THE LONG-TERM OUTCOMES OF PERIPHERAL ARTERIAL DISEASE (2015) (0)
Abstract 11095: Prevalence of Metabolic Syndrome in Healthy Middle-Aged Adults: Insights from the Primary Care Audit of Global Risk Management (PARADIGM) Study (2012) (0)
Abstract 14849: Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME (2020) (0)
C-reactive protein directly attenuates nitric oxide release and bioactivity (2003) (0)
Insulin-like growth factor binding protein 7 as a predictor marker of cardiac remodelling and SGLT2-inhibitor meditated cardiac reverse remodelling in patients with type 2 diabetes and coronary artery disease (2022) (0)
Population-Based Correlation of Regional Intensity of Health Care Utilization and Rates of Amputation Due Diabetes and Peripheral Arterial Disease (2019) (0)
Increased patency with comparable mortality and revascularization risk: Is the case for no‐touch vein harvesting open and shut? (2021) (0)
P760The Ross procedure versus mechanical aortic valve replacement in adults: a systematic review and meta-analysis (2018) (0)
Abstract 11509: Alterations in Cardiac BRCA1 Expression in Human Models of Ischemia and Reperfusion (2011) (0)
Should prophylactic amiodarone therapy be used to prevent atrial tachyarrhythmia after cardiac surgery? (2006) (0)
DIABETES ALTERS THE PROGENITOR PHENOTYPE FROM REGENERATIVE TO PRO-INFLAMMATORY: TRANSLATIONAL IMPLICATIONS FOR CARDIOVASCULAR RISK IN DIABETES (2018) (0)
Empagliflozin Reduces Mortality in Patients with Type 2 Diabetes and a History of Left Ventricular Hypertrophy: A Sub-Analysis of the EMPA-REG OUTCOME Trial (2018) (0)
MORTALITY TRENDS OF RHEUMATIC HEART DISEASE IN HIGH-INCOME COUNTRIES IN MILLENNIUM ERA-AGE PERIOD COHORT ANALYSIS- (2023) (0)
Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply (2021) (0)
P1-74 SERUM INTERLEUKIN-6 LEVELS, NOT GENOTYPE, CORRELATE WITH CORONARY PLAQUE COMPLEXITY (2007) (0)
ESICON 2018 Abstracts (2018) (0)
GEOGRAPHICAL VARIATION IN PATIENT CHARACTERISTICS AND OUTCOMES IN HFPEF (2023) (0)
P1876Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial (2018) (0)
PO297 Time-series Analysis of Elective and Ruptured Abdominal Aortic Aneurysm Repair Trends From 2003 to 2016 (2018) (0)
GLITAZONES AND THE ENDOTHELIUM (GATE) STUDY: EFFECT OF ROSIGLITAZONE ON ENDOTHELIAL FUNCTION IN TYPE 2 DIABETES MELLITUS (2010) (0)
Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. (2020) (0)
Erratum to "Cardiovascular Protection in People With Diabetes": Canadian Journal of Diabetes 2018;42(S1):S162-S169. (2019) (0)
Reply to Kopjar et al. (2014) (0)
DISAGREEMENT BETWEEN PHYSICIAN-REPORTED AND SCORING SYSTEM-BASED STROKE AND BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE STROKE PREVENTION AND RHYTHM INTERVENTIONS IN ATRIAL FIBRILLATION (SPRINT-AF) REGISTRY (2014) (0)
PREVALENCE OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES IN PATIENTS WITH TYPE 2 DIABETES ACROSS MIDDLE EAST AND AFRICA: PRIMARY RESULTS OF THE PACT-MEA STUDY (2023) (0)
Human C-Reactive Protein Paradoxically Protects Against Myocardial Infarction (MI) in Mice: Role of hCRP in Bone Marrow Cell Mobilization (2009) (0)
Abstract 19570: Efficacy and Barriers to Evolocumab Therapy in Real-World, High Risk Secondary Prevention Patients Not at LDL Targets (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Subodh Verma?

Subodh Verma is affiliated with the following schools:

Subodh Verma's Academic­Influence.com Rankings

Why Is Subodh Verma Influential?

Subodh Verma's Published Works

Published Works

What Schools Are Affiliated With Subodh Verma?

Subodh Verma's AcademicInfluence.com Rankings